MediWound Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by MediWound Ltd. on August 19, 2025, covering the month of August 2025. The filing reports on specific insider trading activities rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific share purchase transaction:
- Shares Purchased: 11,200 ordinary shares
- Average Purchase Price: $17.74 per share
- Total Transaction Value: Approximately $198,688 (calculated)
Material Changes
The material event reported is the open market purchase of company stock by two senior executives on August 18, 2025:
- Mr. Nachum (Homi) Shamir: Chairman of the Board of Directors
- Mr. Ofer Gonen: Chief Executive Officer
These purchases were conducted in compliance with the Company's insider trading policy. No other material changes to operations or financial status are disclosed in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items. The document serves solely to disclose the insider transactions and incorporate the report by reference into existing Registration Statements on Forms S-8 and F-3.
Key Facts for Investor Verification
- Verify the total number of shares held by the Chairman and CEO post-transaction to assess their total equity exposure.
- Confirm the current market price of MediWound Ltd. shares relative to the $17.74 purchase price to evaluate the timing of the insider buyback.
- Review the referenced Registration Statements (Forms S-8 and F-3) for details on outstanding equity plans and potential dilution.
- Note that this filing contains no operational or financial performance data for the period.